Turner J H, Martindale A A, de Witt G C, Webb J, Sorby P, Boyd R E
Department of Nuclear Medicine, Fremantle Hospital, Western Australia.
Eur J Nucl Med. 1987;13(8):432-8. doi: 10.1007/BF00292499.
153Sm, a radiolanthanide of half life 46.27 h, has a gamma emission of 0.103 MeV which is well suited to imaging, it is also a moderate energy beta emitter and tumour localization of various 153Sm chelates was evaluated in B16 murine melanoma to assess their endoradiotherapeutic potential. 153Sm was prepared from enriched 152Sm in the Australian Nuclear Science and Technology Organization reactor. 153Sm chelates were prepared from 153Sm-chloride and their chromatographic behaviour characterized. Tumour and organ uptake of 153Sm-chloride, 153Sm-citrate and the 153Sm chelates, DTPA, HEDTA, HIDA, BZ, PBH, PIH and NTA were measured at 1, 6, 24 and 48 h after intravenous administration to C57 black mice bearing either melanotic or amelanotic B16 melanoma of mean size 0.75 cm3. Histopathological examination of the tumours at each passaging assured comparability of the degree of melanogenesis and the absence of necrosis. 153Sm-chloride was immobile on chromatography and the rapid hepatic accumulation of both 153Sm-chloride and 153Sm-citrate was attributed to in vivo formation of a colloid. In contrast, 153Sm-DTPA, moving at the solvent front on chromatography, showed no reticuloendothelial accumulation in vivo and was rapidly excreted by the kidneys without tumour uptake. The other 153Sm chelates were of intermediate stability and all localized in both melanotic and amelanotic tumours, although to a significantly lesser degree than 67Ga-citrate. The relatively high 153Sm-HIDA activity in liver and 153Sm-NTA activity in bone impaired tumour definition, but on imaging of all the 153Sm chelates only 153Sm-DTPA failed to demonstrate the B16 melanoma and the best tumour delineation was obtained using 153Sm-HEDTA.
钐-153是一种半衰期为46.27小时的放射性镧系元素，其γ射线发射能量为0.103兆电子伏特，非常适合成像，它也是一种中等能量的β发射体，在B16小鼠黑色素瘤中评估了各种钐-153螯合物的肿瘤定位情况，以评估它们的内照射治疗潜力。钐-153是在澳大利亚核科学与技术组织的反应堆中由富集的钐-152制备而成。钐-153螯合物由氯化钐-153制备，并对其色谱行为进行了表征。在给平均大小为0.75立方厘米的黑色素或无黑色素的B16黑色素瘤的C57黑小鼠静脉注射后1、6、24和48小时，测量了氯化钐-153、柠檬酸钐-153以及钐-153螯合物二乙三胺五乙酸（DTPA）、羟乙基乙二胺三乙酸（HEDTA）、对氨基苯甲酰亚氨基二乙酸（HIDA）、苯并噻唑（BZ）、对苯二酚硼酸（PBH）、对碘苯甲酰亚氨基二乙酸（PIH）和氮川三乙酸（NTA）在肿瘤和器官中的摄取情况。每次传代时对肿瘤进行组织病理学检查，确保黑色素生成程度的可比性以及无坏死情况。氯化钐-153在色谱上不移动，氯化钐-153和柠檬酸钐-153在肝脏中的快速蓄积归因于体内胶体的形成。相比之下，在色谱上位于溶剂前沿移动的钐-153-DTPA在体内未显示网状内皮系统蓄积，且迅速经肾脏排泄，无肿瘤摄取。其他钐-153螯合物具有中等稳定性，且在黑色素瘤和无黑色素瘤中均有定位，尽管程度明显低于柠檬酸镓-67。肝脏中相对较高的钐-153-HIDA活性和骨骼中钐-153-NTA活性影响了肿瘤的清晰度，但在所有钐-153螯合物的成像中，只有钐-153-DTPA未能显示出B16黑色素瘤，使用钐-153-HEDTA获得了最佳的肿瘤轮廓显示。
